Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Joseph Bisaha, David Jackson


Arno Therapeutics has appointed Joseph Bisaha as its new VP of clinical operations and project management and David Jackson as its VP of diagnostics. In their new positions, both Bisaha and Jackson will support the development of the personalized cancer drug onapristone, Arno's lead product.

Before joining Arno, Bisaha was a clinical research consultant with Kaizen Clinical Services, where he handled Arno's clinical Operations and project management activities. During his 17-year career, he has held various management roles, including associate VP of project management at ImClone Systems and senior director of clinical research and drug development at Ono Pharma.

Jackson comes to Arno from molecular testing firm PrimeraDx where he was VP of business development. Jackson also was senior director of companion diagnostic partnerships at Qiagen Manchester and consulted drug and diagnostics developers on the development and commercialization of personalized medicines and companion tests.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.